1. Home
  2. IMXI vs URGN Comparison

IMXI vs URGN Comparison

Compare IMXI & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMXI
  • URGN
  • Stock Information
  • Founded
  • IMXI 1994
  • URGN 2004
  • Country
  • IMXI United States
  • URGN United States
  • Employees
  • IMXI N/A
  • URGN N/A
  • Industry
  • IMXI Retail: Computer Software & Peripheral Equipment
  • URGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMXI Technology
  • URGN Health Care
  • Exchange
  • IMXI Nasdaq
  • URGN Nasdaq
  • Market Cap
  • IMXI 302.5M
  • URGN 181.2M
  • IPO Year
  • IMXI N/A
  • URGN 2017
  • Fundamental
  • Price
  • IMXI $9.82
  • URGN $14.19
  • Analyst Decision
  • IMXI Buy
  • URGN Strong Buy
  • Analyst Count
  • IMXI 7
  • URGN 8
  • Target Price
  • IMXI $19.60
  • URGN $29.00
  • AVG Volume (30 Days)
  • IMXI 313.4K
  • URGN 2.2M
  • Earning Date
  • IMXI 08-06-2025
  • URGN 08-12-2025
  • Dividend Yield
  • IMXI N/A
  • URGN N/A
  • EPS Growth
  • IMXI 1.60
  • URGN N/A
  • EPS
  • IMXI 1.70
  • URGN N/A
  • Revenue
  • IMXI $652,547,000.00
  • URGN $91,871,000.00
  • Revenue This Year
  • IMXI N/A
  • URGN $39.80
  • Revenue Next Year
  • IMXI $2.93
  • URGN $108.94
  • P/E Ratio
  • IMXI $5.86
  • URGN N/A
  • Revenue Growth
  • IMXI N/A
  • URGN 8.98
  • 52 Week Low
  • IMXI $9.76
  • URGN $3.42
  • 52 Week High
  • IMXI $22.38
  • URGN $18.15
  • Technical
  • Relative Strength Index (RSI)
  • IMXI 37.71
  • URGN 62.88
  • Support Level
  • IMXI $10.10
  • URGN $13.55
  • Resistance Level
  • IMXI $10.49
  • URGN $15.24
  • Average True Range (ATR)
  • IMXI 0.36
  • URGN 0.79
  • MACD
  • IMXI 0.01
  • URGN -0.10
  • Stochastic Oscillator
  • IMXI 5.41
  • URGN 58.76

About IMXI International Money Express Inc.

International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: